Diphtheria

Diphtheria is a severe infectious disease caused by the Gram-positive bacterium Corynebacterium diphtheriae. This pathogen primarily colonizes the upper respiratory tract, but its pathogenicity stems from its ability to produce a potent exotoxin, diphtheria toxin (DT). Not all strains of C. diphtheriae produce this toxin; only those infected by a specific bacteriophage (a virus that infects bacteria) carrying the tox gene are toxigenic.

The DT is an AB toxin, meaning it has two subunits: subunit B binds to specific receptors on host cells, facilitating the entry of subunit A. Once inside the cell, subunit A inhibits protein synthesis by ADP-ribosylating elongation factor 2 (EF-2), a crucial component for translation. This widespread inhibition of protein synthesis leads to cell death, particularly affecting the respiratory epithelium, where it forms the characteristic pseudomembrane.

Systemic effects arise as the toxin circulates, causing damage to the heart (myocarditis), kidneys (nephritis), and nervous system (neuropathy), which are the primary causes of morbidity and mortality.

Diphtheria has plagued humanity for centuries, with documented epidemics dating back to the 17th century. Before the advent of effective medical interventions, it was a leading cause of death, especially among infants and young children. The disease's high mortality rate, often exceeding 50% in severe cases, instilled widespread fear.

The characteristic 'Grecian death' or 'suffocating sickness' described in historical accounts likely referred to the airway obstruction caused by the diphtheritic pseudomembrane. The etymology of the disease's name, derived from the Greek 'diphthera' (leather), aptly describes this leathery membrane. The true nature of the disease remained elusive until the late 19th century, when Edwin Klebs identified the bacterium and Friedrich Löffler demonstrated its causative role, leading to the naming of the organism Corynebacterium diphtheriae.

The pivotal turning point in controlling Diphtheria was the development of the antitoxin and, subsequently, the toxoid vaccine. In the 1890s, Emil von Behring and Kitasato Shibasaburō developed an antitoxin therapy using the serum of immunized animals, a groundbreaking achievement that earned von Behring the first Nobel Prize in Physiology or Medicine. However, the true long-term solution came with the work of Gaston Ramon, who in the 1920s developed a method to inactivate the diphtheria toxin using formalin, creating diphtheria toxoid.

This toxoid, when administered, elicits a protective immune response without causing disease. Routine childhood immunization programs, often combining diphtheria toxoid with tetanus toxoid and acellular pertussis vaccine (DTaP), have been instrumental in reducing Diphtheria incidence to near-elimination in many parts of the world. Booster doses (Tdap) are recommended for adolescents and adults to maintain immunity.

Despite the success of vaccination, Diphtheria remains a significant public health concern in regions with low immunization coverage. Resurgence of the disease in some countries underscores the fragility of herd immunity and the critical need for sustained vaccination efforts. Diphtheria serves as a stark reminder of the potential for infectious diseases to re-emerge if vaccination rates decline.

Furthermore, understanding Diphtheria's pathogenesis provides insights into bacterial toxin mechanisms, which have broader implications for research into other toxin-mediated diseases. The ongoing surveillance and response strategies for Diphtheria highlight the importance of global health security and the continuous need for robust public health infrastructure to prevent and manage outbreaks effectively.